Legionella pneumophila Evades Gamma Interferon-Mediated Growth Suppression through Interleukin-10 Induction in Bone Marrow-Derived Macrophages

Sadako Yoshizawa,¹ Kazuhiro Tateda,¹* Tetsuya Matsumoto,¹ Fumio Gondaira,² Shuichi Miyazaki,¹ Theodore J. Standiford,³ and Keizo Yamaguchi¹

*Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo 143-8540,*¹ *and Denkaseiken Co. Ltd., Gosenshi, Minami-Motomachi 1-2-2, Niigata 959-16,*² *Japan, and Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109-0360*³

Received 20 August 2004/Returned for modification 4 October 2004/Accepted 6 January 2005

We examined the roles of Th1-Th2 cytokine cross talk in *Legionella pneumophila***-infected bone marrowderived (BM) macrophages in the presence of costimulation with interleukin-12 (IL-12) and IL-18. Treatment with gamma interferon (IFN-) alone or treatment with IL-12 in combination with IL-18 resulted in a 3- or 2-log reduction in bacterial numbers, respectively, in BM macrophages, whereas treatment with IL-12 or IL-18** alone had no effect. Significant amounts of $IFN-\gamma$ were detected in the culture supernatants of infected **macrophages stimulated with IL-12 and IL-18 in combination but not independently. Neutralization of IFN by antibody completely abolished the growth inhibitory effects of IL-12 and IL-18. Interestingly, higher infectivity ratios of** *L***.** *pneumophila* **or the addition of increasing concentrations of heat-killed bacteria (HKB) suppressed the production of IFN-, which resulted in the increased intracellular growth of bacteria. Significant amounts of IL-10 were detected in culture supernatants when** *Legionella***-infected macrophages were cocultured with HKB. Furthermore, neutralization of IL-10 by antibody resulted in an increase in IFN production by infected BM macrophages when cocultured with HKB. Treatment of HKB with trypsin but not polymyxin B attenuated the growth-promoting effects of HKB, suggesting the involvement of a protein component(s) in regulation of the growth of** *L***.** *pneumophila***. These findings demonstrate a crucial role of Th1-Th2 cross talk in** *L***.** *pneumophila***-infected BM macrophages. Our results also suggest that** *L***.** *pneumophila* **modulates the cytokine balance from IFN--driven Th1 to more Th2 responses, likely through the induction of IL-10 by a bacterial protein component(s). These data provide new insights not only into the cellular mechanisms of Th1-Th2 cross talk in** *Legionella***-infected macrophages but also into the pathogenesis of** *L***.** *pneumophila* **pneumonia in humans.**

Legionella pneumophila is a gram-negative intracellular pathogen that often causes serious and life-threatening pneumonia in humans (21, 36). A recent epidemiological survey estimated that 17,000 to 50,000 patients with *Legionella* disease have been hospitalized annually in the United States (21, 36). Unfortunately, high mortality rates reaching 50% have been observed, illustrating the fact that *Legionella* pneumonia is still a challenging infectious disease, especially in immunocompromised individuals (10, 35, 47).

Legionella organisms usually infect humans via inhalation of contaminated aerosols from waterborne environmental sources. In the lungs, bacteria infect cells through binding to complement receptors on the surface and multiply predominantly in monocytes/macrophages (16, 24, 28, 34). The development of the A/J mouse model of *L*. *pneumophila* pneumonia has provided a valuable tool for analyzing the pathogenesis of this disease (1, 51). Macrophages of A/J mice are believed to be specifically permissive for *L*. *pneumophila*, and pneumonia induced in these animals resembles human disease in both

pathological findings and cytokine responses (1). Previous studies demonstrated protective roles of Th1 cytokines, such as gamma interferon (IFN- γ), interleukin-12 (IL-12), and IL-18, in an *L*. *pneumophila* infection model (2, 3, 13, 38, 41). For example, we have reported a crucial role of neutrophil-derived IL-12 in driving Th1-type host responses in murine *L*. *pneumophila* pneumonia (46). In contrast, the Th2 cytokine IL-10 facilitates the growth of this organism in macrophages, due in part to IL-10-mediated suppression of Th1 cytokines (33). Th1-polarized cytokine production may be a critical event for resistance to intracellular pathogens, including *Legionella*, although how the Th1-Th2 balance is organized in *L*. *pneumophila* infection is still poorly understood.

IL-12 (6, 20) and IL-18 (31, 48) were separately recognized as IFN-y-inducing factors. Furthermore, recent studies demonstrated that IL-12 and IL-18 synergistically induce the production of IFN- γ in a variety of cell types (25, 31, 32, 52, 53). An essential role of costimulation with IL-12 and IL-18 in the induction of IFN- γ was demonstrated in several infection models, such as *Cryptococcus* (53) and *Listeria* (30). Using a murine *L*. *pneumophila* pneumonia model, Brieland and collaborators demonstrated that blocking of endogenous IL-12 and IL-18 suppressed the production of IFN- γ in the lungs, a result which suggested the synergistic induction of IFN- γ by IL-12 and

^{*} Corresponding author. Mailing address: Department of Microbiology and Infectious Diseases, Toho University School of Medicine, 5-21-16 Ohmorinishi, Ohtaku, Tokyo 143-8540, Japan. Phone: 81-3- 3762-4151, ext. 2396. Fax: 81-3-5493-5415. E-mail: kazu@med.toho-u .ac.jp.

IL-18 in vivo (2). Recently, Munder and collaborators demonstrated that murine bone marrow-derived (BM) macrophages secrete IFN- γ upon stimulation with IL-12 and IL-18 in combination (27). These findings suggest that macrophages not only are key cells responding to $IFN-\gamma$ but also are potent IFN-γ-producing cells. However, the roles and significance of IFN- γ -mediated autocrine macrophage activation in host inflammatory and immunological processes remain to be investigated.

In the present study, we examined the cross talk of Th1 and Th2 cytokines, especially IFN- γ induction and counterregulation by IL-10, in *L*. *pneumophila*-infected BM macrophages treated with IL-12 and IL-18 in combination. Our data suggest that *L*. *pneumophila* modulates the cytokine balance from IFN- --driven Th1 to more Th2 responses, probably through the induction of IL-10 by a bacterial protein component(s). The cellular mechanisms of Th1-Th2 cross talk in *Legionella*-infected macrophages and their contributions to the pathogenesis of *L*. *pneumophila* pneumonia are discussed.

MATERIALS AND METHODS

Medium and reagents. Culturing of cells for infection was performed with RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 1% nonessential amino acids, 1% sodium pyruvate, 1% 2-mercaptoethanol, 1% L-glutamine, and penicillin/streptomycin (GIBCO, Grand Island, NY).

Mice. Female A/J mice, 6 to 8 weeks old (Sankyo Laboratory, Tokyo, Japan), were used in these studies. They were housed and cared for at the Toho University School of Medicine animal facility.

Bacteria. Clinical isolates of *L*. *pneumophila* Suzuki (44), a serogroup 1 strain originally isolated at Toho University Hospital, were grown over 3 to 4 days at 37°C on buffered charcoal-yeast extract (BCYE) agar supplemented with Lcysteine and ferric nitrates. A single colony was transferred to 3 ml of buffered yeast extract broth and incubated overnight at 37°C with constant shaking. The bacterial suspension was transferred to fresh buffered yeast extract broth as serial fivefold dilutions and incubated overnight under the same conditions as those described above. After confirmation of bacterial motility, the concentration of bacteria in the broth was determined by measuring the absorbance at 600 nm. Post-exponential-phase bacteria were used as challenge organisms (4). Heatkilled *L*. *pneumophila* was prepared by incubating the bacterial suspension in normal saline at 60°C for 10 min. After the heat treatment, the sterility of the bacterial suspension was confirmed by plating it on BCYE agar. The numbers of viable bacteria in the challenge suspension and the pre-heat treatment suspension were determined by plating and incubating organisms on BCYE agar for 4 days.

Preparation of BM macrophages. Mouse macrophages were prepared from bone marrow exudates of female A/J mouse femurs as described previously (5, 43). The cells were seeded in 96-well tissue culture plates $(10⁴$ cells/well) overnight and used as BM macrophages. After the medium was changed, the BM macrophages were infected with *L*. *pneumophila* Suzuki at several infectivity ratios (macrophage/bacteria, 1:0.2 to 1:1). At 2 h after infection, nonphagocytized and nonadherent bacteria were removed by two washes with medium. The infected macrophages were cultured for an additional 7 days at 37°C in a humidified atmosphere containing 5% CO₂. In some experiments, various concentrations of heat-killed *L*. *pneumophila* were added to the infected macrophages 2 h after infection.

Addition of cytokines and neutralizing antibodies. Recombinant mouse cytokines (IL-12, IL-18, and IFN- γ) and antibodies (anti-IFN- γ or anti-IL-10) were added to the infected macrophages 1 day after infection with *L*. *pneumophila*. All cytokines and antibodies used were obtained from R&D Systems (Minneapolis, MN).

Determination of bacterial numbers. At various times after infection, culture supernatants were collected and infected macrophages were lysed by mechanical disruption in phosphate-buffered saline (pH 7.4). Harvested bacterial suspensions were plated on BCYE agar as serial 10-fold dilutions and incubated at 37°C for 4 days.

ELISAs for cytokines. The suspensions used for the determination of bacterial numbers were centrifuged (10,000 rpm, 5 min). The supernatants were collected for cytokine assays and stored at -80° C until used. The concentrations of IL-10,

tumor necrosis factor alpha (TNF- α), and IFN- γ were determined by sandwich enzyme-linked immunosorbent assays (ELISAs) with antibody pairs from R&D Systems in accordance with the manufacturer's instructions. The sensitivities of the ELISAs for the cytokines were 31 pg/ml for IL-10, 30 pg/ml for IFN- γ , and 16 pg/ml for TNF- α .

Trypsin and polymyxin B treatments of heat-killed *L***.** *pneumophila* **and effects of** *Legionella* **lipopolysaccharide (LPS) on bacterial numbers.** Heat-killed *L*. *pneumophila* (approximately 10¹⁰ CFU/ml) was diluted to the desired concentrations in RPMI 1640 medium. Trypsin treatment was performed as described previously (9, 12). Briefly, heat-killed *L*. *pneumophila* Suzuki was treated with trypsin (Sigma) for 2 h, and then soybean trypsin inhibitor (Sigma) was added for 1 h. This suspension was added to wells 2 h after infection. Final concentrations of trypsin were 80, 2,000, and 50,000 μ g/ml, and that of trypsin inhibitor was 2.5 mg/ml. According to the manufacturer's instructions, 1 mg of trypsin inhibitor will inhibit 1.3 to 2.5 mg of trypsin. We did not observe significant effects of these concentrations of trypsin and/or trypsin inhibitor on bacterial numbers in the presence or absence of IL-12 plus IL-18.

Polymyxin B was obtained from Pfizer Japan Inc., and the suspension form of heat-killed *L*. *pneumophila* was treated with polymyxin B as described previously (49). Polymyxin B was incubated with the suspension of heat-killed bacteria for 3 h at room temperature. This suspension was added to wells 2 h after infection. Final concentrations of polymyxin B were 2 and 50 μ g/ml.

LPS of *L*. *pneumophila* Suzuki was prepared as described previously (14). Purified LPS demonstrated 429,500 endotoxin units/ml, which is equivalent to approximately 2 \times 10⁹ to 4 \times 10⁹ CFU/ml. *L. pneumophila*-infected macrophages were incubated with various concentrations of *Legionella* LPS, and bacterial numbers in wells were determined on day 7.

RESULTS

Effects of Th1 cytokines on the growth of *L***.** *pneumophila* **in BM macrophages.** BM macrophages from A/J mice were infected with *L*. *pneumophila* at an infectivity ratio of 1 (macrophages:bacteria, 1:1) on day 0, and then macrophages were treated with IL-12, IL-18, IL-12 plus IL-18, or IFN- γ (20 ng/ml, each) on day 1. Bacterial numbers at day 0, 1, 2 and 7 after the infection were then determined $(n = 5)$. As shown in Fig. 1, *L*. *pneumophila* displayed continuous growth in untreated control BM macrophages, reaching a concentration of approximately $10⁶$ CFU/ml on day 7. We did not observe growth inhibitory effects when macrophages were treated with IL-12 or IL-18 separately. In contrast, IL-12 plus IL-18, or IFN- γ alone resulted in a significant reduction in bacterial numbers on day 7. Specifically, incubation with IL-12 and IL-18 in combination, or IFN- γ induced 2- and 3-log reductions in bacterial numbers on day 7, respectively. These data suggest that the combination of IL-12 and IL-18 induces growth inhibition of *L*. *pneumophila* in BM macrophages, even at the concentrations in which each cytokine is ineffective individually. Furthermore, our data indicates that IFN- γ serves as the most potent stimulus for bacterial growth inhibition by macrophages.

TNF-α and IFN- γ expression in culture supernatants of **infected BM macrophages treated with IL-12 plus IL-18.** To define the nature of growth inhibitory effects induced by treatment of BM macrophages with IL-12 and IL-18 in combination, we examined levels of TNF- α and IFN- γ in culture supernatants of the infected BM macrophages. In these experiments, infected BM macrophages were treated with IL-12 or IL-18 (10 and 20 ng/ml) alone or in combination on day 1, incubated for additional 6 days, then culture supernatants were collected on day 7 and examined for TNF- α and IFN- γ by ELISAs ($n = 5$). As shown in Fig. 2, we were unable to detect significant amounts of TNF- α in any of these treatment groups. In contrast, the combination of IL-12 and IL-18 (at doses of 10 and 20 ng/ml) induced significant IFN- γ pro-

Days after infection

FIG. 1. Effects of Th1 cytokines on the growth of *L*. *pneumophila* in BM macrophages. BM macrophages (10⁵ cells) were infected with *L*. *pneumophila* (10⁵ CFU; infectivity ratio, 1:1) on day 0. Cytokines (20 ng/ml) were added to the wells of macrophage cultures at 24 h after infection (day 1). At the indicated times, supernatants and macrophages were collected and viable bacterial numbers were compared in the control group (open circle) and in groups treated with IL-12 (closed circle), IL-18 (open square), IL-12 plus IL-18 (closed square), and IFN- γ (open triangle). The results are expressed as means \pm standard deviations for five wells per group. Similar results were obtained in three independent experiments. An asterisk indicates a *P* value of ≤ 0.05 in a comparison with the control group.

duction in *Legionella*-infected BM macrophages, whereas each cytokine alone failed to induce detectable levels of IFN- γ . These data suggest that the treatment of infected BM macrophages with IL-12 and IL-18 in combination stimulates induc-

tion of IFN- γ , which may be associated with growth inhibitory effects on *L*. *pneumophila*.

Effects of IFN- neutralization on suppression of the growth of *L***.** *pneumophila* **mediated by IL-12 and IL-18 in combination.** To further analyze the growth inhibitory effects observed by treatment of macrophages with IL-12 plus IL-18, we examined the effects of anti-IFN- γ antibodies on the growth of L . pneumophila in BM macrophages. Anti-IFN-γ antibodies (100, 300, and 1,000 ng/ml), in combination with IL-12 plus IL-18 (20 ng/ml), were added to the infected BM macrophages on day 1. Bacterial numbers in wells were determined on day $7 (n = 5)$. As previously noted, a significant reduction in bacterial numbers in BM macrophages was observed when these cells were treated with IL-12 plus IL-18. Under these experimental conditions, anti-IFN- γ antibodies abolished the growth-suppressive effects of therapy with IL-12 plus IL-18 (Fig. 3). Anti-IFN- γ antibodies effects were observed in a concentrationdependent fashion, and 1,000 ng/ml of antibody completely restored the growth of *L*. *pneumophila* to the control level. These results demonstrate that the induction of IFN- γ induction by IL-12 plus IL-18 was the major mechanism accounting for the growth inhibitory effects observed.

Suppression of IFN- γ production by live and heat-killed L **.** *pneumophila***.** To further characterize roles of Th1-Th2 cytokines in the pathogenesis of *L*. *pneumophila* infection, we examined IFN- γ induction in the setting of several magnitudes of infectivity ratio. As previously shown (Fig. 2), IFN- γ production was observed in the supernatants of *L*. *pneumophila*-infected BM macrophages when these cells were treated with IL-12 and IL-18. Interestingly, we observed less IFN- γ production in higher infectivity ratio although it was not statistically significant, as shown in Fig. 4A. These data suggest that *L*. pneumophila organism may suppress IFN- γ production from BM macrophages. However, we could not exclude the possibility of cytotoxic effects of bacteria at higher infectivity ratio as a reason for a reduction of IFN- γ , because previous data demonstrated that *Legionella* organisms induce cell death of mac-

FIG. 2. TNF- α and IFN- γ levels in culture supernatants of infected BM macrophages treated with IL-12 plus IL-18. Cytokines at concentrations of 10 ng/ml (open bars) and 20 ng/ml (closed bars) were added to the wells of *L*. *pneumophila*-infected BM macrophages (105 cells) at 24 h after infection $(n = 5)$. Culture supernatants were collected 7 days after infection, and TNF- α and IFN- γ levels were determined. The results represent means \pm standard deviations for five wells. Similar results were obtained in at least two independent experiments. An asterisk indicates a *P* value of ≤ 0.05 in a comparison with the control group.

FIG. 3. Effects of anti-IFN- γ antibodies on suppression of the growth of *L. pneumophila* in BM macrophages treated with IL-12 plus IL-18. Cytokines (20 ng/ml) were added to the wells of *L. pneumophila*-infected BM macrophages (10⁵ cells) at 24 h after infection ($n = 5$). Several concentrations of anti-IFN- γ antibodies were added simultaneously with IL-12 and IL-18. Bacterial numbers in the wells were determined on day 7 after infection. The results represent means \pm standard deviations for five wells. Similar results were obtained in at least two independent experiments. An asterisk indicates a P value of ≤ 0.05 in a comparison with the group receiving IL-12 plus IL-18 but not antibodies.

rophages, probably through induction of apoptosis (29, 54). To simplify the experimental conditions, we next examined effects of heat-killed *L. pneumophila* on IFN-γ production in BM macrophages. In these experimental conditions, we did not observe decrease of macrophage viability in the presence of heat-killed organisms. As shown in Fig. 4B, heat-killed *L*. pneumophila reduced production of IFN- γ in a dose-dependent fashion, similar to that observed with live organisms (Fig. 4B). These data demonstrate that *L*. *pneumophila* suppress IFN- γ production from macrophages stimulated with IL-12

plus IL-18. Moreover, our data suggest that heat-stable components of the organisms may be responsible for this IFN- γ suppressing activity in BM macrophages.

Heat-killed *L***.** *pneumophila* **enhances the replication of live organisms in BM macrophages.** Next, we examined effects of heat-killed *L*. *pneumophila* on growth of the organisms in BM macrophages. Various concentrations of heat-killed organisms were added to the culture of infected BM macrophages 2 h after the infection with live *L*. *pneumophila*, and then bacterial numbers were compared on day 7 ($n = 5$). Interestingly, the

FIG. 4. Suppression of IFN- γ production by live and heat-killed *L. pneumophila.* (A) BM macrophages (10⁵ cells) were infected with several concentrations of bacteria on day 0, and IL-12 plus IL-18 (10 ng/ml) was added to the wells on day 1. Culture supernatants were collected on day 7, and the concentrations of IFN- γ were determined $(n = 5)$. (B) BM macrophages (10⁵ cells) were infected with 10⁵ CFU of bacteria on day 0. Heat-killed bacteria (HKB) and IL-12 plus IL-18 (10 ng/ml) were added to the wells at 2 h and 24 h after infection, respectively. Culture supernatants were collected on day 7, and the concentrations of IFN- γ were determined ($n = 5$). The results are expressed as means \pm standard deviations for five wells. Similar results were obtained in at least two independent experiments. An asterisk indicates a P value of <0.05 in a comparison with the groups not receiving heat-killed bacteria.

FIG. 5. Heat-killed *L*. *pneumophila* augments replication of the organisms in BM macrophages. BM macrophages (105 cells) were infected with *L*. *pneumophila* on day 0. Heat-killed bacteria (HKB) and IL-12 plus IL-18 (10 ng/ml) were added to the wells at 2 h and 24 h after infection, respectively. Seven days after infection, bacterial numbers in the wells were determined. The results are expressed as means \pm standard deviations for five wells. Similar results were obtained in at least two independent experiments. A single asterisk indicates a P value of <0.05 and a double asterisk indicates a *P* value of <0.01 in a comparison with the group receiving IL-12 plus IL-18 but not heat-killed bacteria.

addition of heat-killed organisms promoted the growth of *L*. *pneumophila* (Fig. 5). This growth promoting effect of heatkilled organisms was concentration dependent, and more than a 1-log increase on bacterial numbers was observed when 1:10 heat-killed organisms (macrophages:heat-killed bacteria) were added to the culture. These data are consistent with the observed reduction of IFN- γ in the presence of heat-killed organisms. Taken together, the present results suggest that IFN-γ is a critical factor for growth suppression of *L*. *pneumophila*, and the presence of heat-killed organisms suppresses IFN- γ induction, which may be associated with the growth promotion of this organism in BM macrophages.

Heat-killed *L***.** *pneumophila* **induces IL-10 production in infected BM macrophages.** To examine the potential mechanism(s) of suppression of IFN- γ by heat-killed organisms, we determined IL-10 levels in the infected BM macrophages cocultured with heat-killed organisms $(n = 5)$. As shown in Fig. 6A, significant amounts of IL-10 were detected in the culture supernatants of infected BM macrophages when these cells were cocultured with 1:2 heat-killed organisms (macrophages: heat-killed organisms). These results prompted us to examine effect of anti-IL-10 antibodies on IFN- γ production in these experimental conditions. As shown in Fig. 6B, the neutralization of IL-10 by specific antibody resulted in significant increase of IFN- γ in the infected BM macrophages when cocultured with heat-killed organisms. These findings suggest an important role of IL-10 induction by heat-killed *L*. *pneumo* $phila$, which may explain, at least in part, suppression of IFN- γ and the resultant growth promotion of the organisms observed in the presence of heat-killed bacteria.

Characterization of a bacterial component(s) responsible for growth promotion in heat-killed *L***.** *pneumophila***.** We next characterized the bacterial component(s) responsible for growth inhibitory effects mediated by heat-killed organisms. Heat-killed bacteria were treated with the proteinase trypsin for protein digestion (12) or polymyxin B for lipopolysaccharide inactivation (49), then added to the culture of infected BM macrophages, and the bacterial numbers on day 7 were examined. As shown in Fig. 7, the treatment of heat-killed *L*. *pneumophila* with trypsin significantly abolished the growth enhancing effects of heat-killed organisms, whereas inactivation of lipopolysaccharide by polymyxin B failed to alter growth of bacteria. These data suggests that a heat-stable protein component(s) of *L*. *pneumophila* may be responsible for growth promoting effects observed in the infected BM macrophages cocultured with heat-killed organisms.

Effects of *Legionella* **LPS on bacterial numbers.** Finally, we examined effects of purified *L*. *pneumophila* LPS on bacterial numbers in macrophages. As shown in Fig. 8, we observed reductions in bacterial numbers in the presence of *Legionella* LPS, in a concentration-dependent manner. The *Legionella* LPS effects were demonstrated in despite of the presence or absence of IL-12 plus IL-18. These data are consistent with data of Fig. 7, and further suggested that *Legionella* LPS is not an effector of growth promotion observed in the presence of heat-killed bacteria.

DISCUSSION

In the present study, cross talk between Th1 and Th2 cytokines was examined in *L*. *pneumophila*-infected BM macrophages. Our data are consistent with previous reports indicating a critical role of IFN- γ in anti-*Legionella* activity, and further demonstrate that *L*. *pneumophila* modulates cytokine balance, probably through IL-10-mediated suppression of IFN- γ production. The present results highlight the critical involvement of bacterial protein component(s), not only in Th1-Th2 cytokine cross talk, but also in regulation of growth of *L*. *pneumophila*.

Synergistic effects of IL-12 and IL-18 on IFN- γ induction has

FIG. 6. Heat-killed *L*. *pneumophila* induces IL-10 production in *Legionella*-infected BM macrophages. (A) BM macrophages (105 cells) were infected with *L*. *pneumophila* on day 0. Heat-killed bacteria (HKB) and IL-12 plus IL-18 (10 ng/ml) were added to the wells at 2 h and 24 h after infection, respectively. Seven days after infection, IL-10 production in supernatants was determined. The results are expressed as means \pm standard deviations for five wells. Similar results were obtained in at least two independent experiments. An asterisk indicates a P value of ≤ 0.05 in a comparison with the group receiving IL-12 plus IL-18 but not heat-killed bacteria. (B) BM macrophages (105 cells) were infected with *L*. *pneumophila* on day 0. Heat-killed bacteria (HKB) were added to the wells at 2 h after infection. Anti-IL-10 antibodies (Ab) and IL-12 plus IL-18 (10 ng/ml) were added to the wells at 24 h after infection. Seven days after infection, IFN-- production in the wells was determined. The results are expressed as means \pm standard deviations for five wells. Similar results were obtained in at least two independent experiments. An asterisk indicates a *P* value of <0.05 in a comparison with the group receiving IL-12 plus IL-18 and heat-killed bacteria but not antibodies.

been demonstrated in several types of cells, such as T cells (25, 37), B cells (52) and NK cells (53). Furthermore, a recent report demonstrated that murine macrophages also produce efficient amount of IFN- γ in response to these cytokines, which suggests a novel pathway of autocrine macrophage activation (27). Salins and associates have demonstrated that expression of IFN-γ mRNA was detected in the *Legionella*-infected macrophages of BALB/c mice (growth restrictive), but not in the macrophages of A/J mice (growth-permissive), further supporting the importance of macrophage-derived IFN- γ in in vitro *L*. *pneumophila* infection (38). Brieland and collaborators have demonstrated that blocking of endogenous IL-12 and IL-18 by administration of specific neutralization antibody suppressed production of IFN- γ in lungs of mice infected with L . *pneumophila*, confirming a contribution of IL-12 and IL-18 to induction of IFN- γ in vivo (2). In this regard, we did not find a protective role of exogenous IL-12 in neutropenic A/J mouse model of *L*. *pneumophila* pneumonia, although combination treatment of IL-12 and IL-18 was not examined (46). In the present study, we observed IFN-γ production in *L. pneumophila*-infected BM macrophage from A/J mice, although costimulation with IL-12 and IL-18 was required. Since neutralization of IFN- γ by specific antibody completely abolished the growth inhibitory effects of treatment with IL-12 plus IL-18, it was concluded that IFN- γ -mediated macrophage activation is the principle reason for exaggerated bactericidal activity. These data suggest that production of macrophage-associated IFN- γ under costimulation with IL-12 and IL-18 may be important for regulation of growth of intracellular pathogens, including *L*. *pneumophila*. Moreover, our results suggest a potential role of therapy with IL-12 plus IL-18 against *L*. *pneumophila* infection, which is an ongoing study in our laboratory.

During these experiments, we noted suppression of IFN- γ when BM macrophages were infected with higher numbers of bacteria, which prompted us to examine effect of heat-killed organisms. Interestingly, we observed that heat-killed *L*. *pneumophila* also inhibited the production of IFN- γ in a dosedependent manner (Fig. 4). The presence of heat-killed organisms in *L*. *pneumophila*-infected BM macrophages promoted the bacterial growth, an effect which correlated with suppression of IFN- γ . These results suggest that cellular component(s) of *L*. *pneumophila* may produce extracellular signals that modulate IFN- γ production and intracellular multiplication of bacteria in BM macrophages. Matsunaga and colleagues demonstrated that LPS-induced production of IL-12 was downregulated in macrophages by infection with virulent *L*. *pneumophila*, but other cytokines, such as IL-6 and IL-10, were not affected (22). They also suggested an involvement of the mitogen-activated protein kinase cascade in the inhibition of IL-12 production by *L*. *pneumophila* (23) Since virulent *L*. *pneumophila*, but not avirulent or UV-killed bacteria, suppressed IL-12 production in macrophages, it was speculated that IL-12 suppression may be dependent on *L*. *pneumophila* virulence and its viability in the macrophages. Although a correlation between IL-12 suppression by virulent organisms and the present data of IFN- γ inhibition by heat-killed L . *pneumophila* is unknown, altering the production of the Th1 driving cytokines may be a critical means by which bacteria evade host immune systems.

Significant amounts of IL-10 were detected in *L*. *pneumophila*-infected BM macrophages when these cells were cocultured with heat-killed bacteria. Furthermore, neutralization of IL-10 by specific antibody resulted in a reciprocal increase of IFN- γ in these culture conditions. These data suggest that the

FIG. 7. Characterization of a bacterial component(s) responsible for bacterial growth promotion by heat-killed *L*. *pneumophila*. BM macrophages (105 cells) were infected with *L*. *pneumophila* on day 0. Heat-killed bacteria (HKB) and IL-12 plus IL-18 (10 ng/ml) were added to the wells at 2 h and 24 h after infection, respectively. Trypsin-treated (80, 2,000, or 50,000 μ g/ml) or polymyxin B-treated (2 or 50 μ g/ml) heat-killed bacteria were added to the wells of infected BM macrophages as described in Materials and Methods. Seven days after infection, bacterial numbers in the wells were determined. The results are expressed as means \pm standard deviations for five wells. Similar results were obtained in at least two independent experiments. Single and double asterisks indicate P values of <0.05 and <0.01, respectively, in a comparison with the groups not receiving trypsin treatment.

production of IL-10 in response to heat-killed organisms contributes to IFN- γ suppression, which may be associated with growth promotion effects by heat-killed *L*. *pneumophila*. The present results are in agreement with the notion that bacteria can alter host cytokine networks as a means to enhance pathogenicity (50). IL-10 is a strong suppressor for IFN- γ and a key factor for driving Th2-type host responses. The role of IL-10 in microbial infection has been investigated for several bacterial and parasitic pathogens (26). In particular, a pathogen-mediated IL-10 production as microbial strategy to evade host immune system was demonstrated in *Leishmania major* (17) and *Yersinia* spp (39, 40). Sing and associates have demonstrated that *Y*. *enterocolitica* releases a virulence factor LcrV, which induces IL-10 through Toll-like receptor-2 and CD14 (40).

FIG. 8. Effects of *Legionella* LPS on the growth of bacteria. BM macrophages (105 cells) were infected with *L*. *pneumophila* on day 0. *Legionella* LPS (in multiplicities of infection) and IL-12 plus IL-18 (10 ng/ml) were added to the wells at 2 h and 24 h after infection, respectively. Seven days after infection, bacterial numbers in the wells were determined. The results are expressed as means \pm standard deviations for five wells. Similar results were obtained in at least two independent experiments. An asterisk indicates a P value of <0.05 in a comparison with the control group.

Although LcrV homolog, PcrV, has been discovered in *Pseudomonas aeruginosa* as a part of type III protein secretion/ translocation apparatus (39), the presence of LcrV homolog in *L*. *pneumophila* has not yet been demonstrated.

L. *pneumophila* possesses a variety of virulence factors, including LPS, flagella, heat-shock protein (Hsp60) and toxins (7, 42). More recently, *lvgA*, a surface-expressed novel virulence factor, has been identified (8, 9). Since treatment with a protease trypsin, but not the LPS inhibitor polymyxin B, decreased the growth promoting effect by heat-killed organisms, it appears likely that protein component(s) of bacteria may be responsible for these mechanisms. In fact, we did not observe the growth promotion effect by adding purified *Legionella* LPS. On the other hand, *Legionella* flagella (15) and a toxin (11) have been reported thus far as protein components with heatstable characteristics. Hawn and colleagues have reported that flagella proteins of *L*. *pneumophila* are a principal stimulant of proinflammatory cytokine production in lung epithelial cells (15). They demonstrated that heat-killed *L*. *pneumophila* (65°C, 15 min), but not flagellum-deficient mutant, stimulated IL-8 production in A549 and Calu-3 cells, although the effects of *Legionella* flagella proteins on macrophages were not examined. Another important characteristic of *L*. *pneumophila* is the surface expression of Hsp60, a member of the GroEL family of chaperonins, as a virulence factor (12). In a study addressing bacterial Hsp60-host cell interactions, it was shown that the pretreatment of HeLa cells with Hsp60 of *L*. *pneumophila* reduced the adherence and invasiveness of bacteria at 3 h after infection (12), although the effect of Hsp60 pretreatment on long-term growth, or the stability of this protein after heat treatment has not been investigated. Which protein component(s) of *L*. *pneumophila* is responsible for the growth promotion effects, as well as potential receptor-ligand interaction and down-stream signaling mechanisms governing growth permissiveness in macrophages, are of great interest.

While our study has identified a protein component(s) of *L*. *pneumophila* as an autocrine and/or paracrine enhancer of intracellular growth within macrophages, the roles and significance of these phenomenon in vivo remain to be investigated. *L*. *pneumophila* pneumonia is characterized by severe hypoxemia and a high frequency of complications, such as acute respiratory distress syndrome and multiple organ failure (10, 35, 47). It is well known that patients with *L*. *pneumophila* pneumonia excrete bacterial antigens into urine, which is now widely accepted as a diagnostic tool for the disease. Interestingly, urinary antigens are generally detectable within a few days of illness onset and can remain so for several months to 300 days after initiation of appropriate antimicrobial therapy (18). These findings suggest that bacteria or at least bacterial components/products may exist at sites of infection during those periods. Previously, we found less extensive IFN- γ and IL-12 responses in the lungs when larger numbers of *L*. *pneumophila* organisms were inoculated into the lungs of A/J mice, suggesting the suppression of Th1-type cytokine responses by this organism in vivo (unpublished results). In contrast, in the serum of *L*. *pneumophila* pneumonia patients, we did not observe a correlation between the severity of disease and levels of IFN- γ , although most patients consistently demonstrated strong Th1-type cytokine responses (45). Recently, Lettinga and associates reported reduced IFN- γ responses in patients

who had recovered from *L*. *pneumophila* pneumonia 1 year earlier, in comparison with control individuals who were also exposed but had not developed the disease (19). Since smaller amounts of IFN- γ were released after whole-blood stimulation with LPS or IL-12 in the former patients, they concluded that impaired IFN- γ production may contribute to susceptibility to *L*. *pneumophila* infection. Based on our current observations, an alternative interpretation of these results is that suppression of IFN-- production may be mediated by ongoing exposure to *L*. *pneumophila* or its antigens, although the duration and persistence of IFN- γ -suppressing effects by heat-killed bacteria have not yet been examined. Further investigations are warranted in order to better define the mechanisms of pathogenesis in *L*. *pneumophila* infection, the molecular and cellular aspects of Th1-Th2 cytokine cross talk, and the clinical significance of these responses in disease.

ACKNOWLEDGMENTS

We greatly appreciate suggestions made by Paul H. Edelstein, University of Pennsylvania. We also thank Tsuneharu Maeda and Chiharu N. Kimura for technical assistance and helpful discussions.

This work was supported by a grant-in-aid for scientific research from the Ministry of Education, Science and Culture of Japan.

REFERENCES

- 1. **Brieland, J., P. Freeman, R. Kunkel, C. Chrisp, M. Hurley, J. Fantone, and C. Engleberg.** 1994. Replicative *Legionella pneumophila* lung infection in intratracheally inoculated A/J mice. A murine model of human Legionnaires' disease. Am. J. Pathol. **145:**1537–1546.
- 2. **Brieland, J. K., C. Jackson, S. Hurst, D. Loebenberg, T. Muchamuel, R. Debets, R. Kastelein, T. Churakova, J. Abrams, R. Hare, and A. O'Garra.** 2000. Immunomodulatory role of endogenous interleukin-18 in gamma interferon-mediated resolution of replicative *Legionella pneumophila* lung infection. Infect. Immun. **68:**6567–6573.
- 3. **Brieland, J. K., D. G. Remick, M. L. LeGendre, N. C. Engleberg, and J. C. Fantone.** 1998. In vivo regulation of replicative *Legionella pneumophila* lung infection by endogenous interleukin-12. Infect. Immun. **66:**65–69.
- 4. **Byrne, B., and M. S. Swanson.** 1998. Expression of *Legionella pneumophila* virulence traits in response to growth conditions. Infect. Immun. **66:**3029– 3034.
- 5. **Celada, A., P. W. Gray, E. Rinderknecht, and R. D. Schreiber.** 1984. Evidence for a gamma-interferon receptor that regulates macrophage tumori-cidal activity. J. Exp. Med. **160:**55–74.
- 6. **Chan, S. H., B. Perussia, J. W. Gupta, M. Kobayashi, M. Pospisil, H. A. Young, S. F. Wolf, D. Young, S. C. Clark, and G. Trinchieri.** 1991. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med. **173:**869–879.
- 7. **Cianciotto, N. P.** 2001. Pathogenicity of *Legionella pneumophila*. Int. J. Med. Microbiol. **291:**331–343.
- 8. **Edelstein, P. H., M. A. Edelstein, F. Higa, and S. Falkow.** 1999. Discovery of virulence genes of *Legionella pneumophila* by using signature tagged mutagenesis in a guinea pig pneumonia model. Proc. Natl. Acad. Sci. USA **96:**8190–8195.
- 9. **Edelstein, P. H., B. Hu, F. Higa, and M. A. Edelstein.** 2003. LvgA, a novel *Legionella pneumophila* virulence factor. Infect. Immun. **71:**2394–2403.
- 10. **el-Ebiary, M., X. Sarmiento, A. Torres, S. Nogue, E. Mesalles, M. Bodi, and J. Almirall.** 1997. Prognostic factors of severe *Legionella* pneumonia requiring admission to ICU. Am. J. Respir. Crit. Care Med. **156:**1467–1472.
- 11. **Friedman, R. L., B. H. Iglewski, and R. D. Miller.** 1980. Identification of a cytotoxin produced by *Legionella pneumophila*. Infect. Immun. **29:**271–274.
- 12. **Garduno, R. A., E. Garduno, and P. S. Hoffman.** 1998. Surface-associated hsp60 chaperonin of *Legionella pneumophila* mediates invasion in a HeLa cell model. Infect. Immun. **66:**4602–4610.
- 13. **Gebran, S. J., Y. Yamamoto, C. Newton, T. W. Klein, and H. Friedman.** 1994. Inhibition of *Legionella pneumophila* growth by gamma interferon in permissive A/J mouse macrophages: role of reactive oxygen species, nitric oxide, tryptophan, and iron(III). Infect. Immun. **62:**3197–3205.
- 14. **Girard, R., T. Pedron, S. Uematsu, V. Balloy, M. Chignard, S. Akira, and R. Chaby.** 2003. Lipopolysaccharides from *Legionella* and *Rhizobium* stimulate mouse bone marrow granulocytes via Toll-like receptor 2. J. Cell Sci. **116:** 293–302.
- 15. **Hawn, T. R., A. Verbon, K. D. Lettinga, L. P. Zhao, S. S. Li, R. J. Laws, S. J. Skerrett, B. Beutler, L. Schroeder, A. Nachman, A. Ozinsky, K. D. Smith,**

and A. Aderem. 2003. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to Legionnaires' disease. J. Exp. Med. **198:**1563–1572.

- 16. **Horwitz, M. A., and S. C. Silverstein.** 1980. Legionnaires' disease bacterium (*Legionella pneumophila*) multiples intracellularly in human monocytes. J. Clin. Investig. **66:**441–450.
- 17. **Kane, M. M., and D. M. Mosser.** 2001. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. **166:**1141–1147.
- 18. **Kohler, R. B., W. C. Winn, Jr., and L. J. Wheat.** 1984. Onset and duration of urinary antigen excretion in Legionnaires' disease. J. Clin. Microbiol. **20:** 605–607.
- 19. **Lettinga, K. D., S. Weijer, P. Speelman, J. M. Prins, T. Van Der Poll, and A. Verbon.** 2003. Reduced interferon-gamma release in patients recovered from Legionnaires' disease. Thorax **58:**63–67.
- 20. **Locksley, R. M.** 1993. Interleukin 12 in host defense against microbial pathogens. Proc. Natl. Acad. Sci. USA **90:**5879–5880.
- 21. **Marston, B. J., H. B. Lipman, and R. F. Breiman.** 1994. Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality. Arch. Intern. Med. **154:**2417–2422.
- 22. **Matsunaga, K., T. W. Klein, C. Newton, H. Friedman, and Y. Yamamoto.** 2001. *Legionella pneumophila* suppresses interleukin-12 production by macrophages. Infect. Immun. **69:**1929–1933.
- 23. **Matsunaga, K., H. Yamaguchi, T. W. Klein, H. Friedman, and Y. Yamamoto.** 2003. *Legionella pneumophila* suppresses macrophage interleukin-12 production by activating the p42/44 mitogen-activated protein kinase cascade. Infect. Immun. **71:**6672–6675.
- 24. **McDade, J. E., C. C. Shepard, D. W. Fraser, T. R. Tsai, M. A. Redus, and W. R. Dowdle.** 1977. Legionnaires' disease: isolation of a bacterium and demonstration of its role in other respiratory disease. N. Engl. J. Med. **297:**1197–1203.
- 25. **Micallef, M. J., T. Ohtsuki, K. Kohno, F. Tanabe, S. Ushio, M. Namba, T. Tanimoto, K. Torigoe, M. Fujii, M. Ikeda, S. Fukuda, and M. Kurimoto.** 1996. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur. J. Immunol. **26:**1647–1651.
- 26. **Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra.** 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. **19:** 683–765.
- 27. **Munder, M., M. Mallo, K. Eichmann, and M. Modolell.** 1998. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J. Exp. Med. **187:**2103–2108.
- 28. **Nash, T. W., D. M. Libby, and M. A. Horwitz.** 1984. Interaction between the Legionnaires' disease bacterium (*Legionella pneumophila*) and human alveolar macrophages. Influence of antibody, lymphokines, and hydrocortisone. J. Clin. Investig. **74:**771–782.
- 29. **Neumeister, B., M. Faigle, K. Lauber, H. Northoff, and S. Wesselborg.** 2002. *Legionella pneumophila* induces apoptosis via the mitochondrial death pathway. Microbiology **148:**3639–3650.
- 30. **Nomura, T., I. Kawamura, K. Tsuchiya, C. Kohda, H. Baba, Y. Ito, T. Kimoto, I. Watanabe, and M. Mitsuyama.** 2002. Essential role of interleukin-12 (IL-12) and IL-18 for gamma interferon production induced by listeriolysin O in mouse spleen cells. Infect. Immun. **70:**1049–1055.
- 31. **Okamura, H., H. Tsutsi, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al.** 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature **378:**88–91.
- 32. **Okamura, H., H. Tsutsui, S. Kashiwamura, T. Yoshimoto, and K. Nakanishi.** 1998. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv. Immunol. **70:**281–312.
- 33. **Park, D. R., and S. J. Skerrett.** 1996. IL-10 enhances the growth of *Legionella pneumophila* in human mononuclear phagocytes and reverses the protective effect of IFN-gamma: differential responses of blood monocytes and alveolar macrophages. J. Immunol. **157:**2528–2538.
- 34. **Payne, N. R., and M. A. Horwitz.** 1987. Phagocytosis of *Legionella pneumophila* is mediated by human monocyte complement receptors. J. Exp. Med. **166:**1377–1389.
- 35. **Pedro-Botet, M. L., M. Sabria-Leal, N. Sopena, J. M. Manterola, J. Morera, R. Blavia, E. Padilla, L. Matas, and J. M. Gimeno.** 1998. Role of immunosuppression in the evolution of Legionnaires' disease. Clin. Infect. Dis. **26:**14–19.

Editor: J. L. Flynn

- 36. **Reingold, A. L.** 1988. Role of legionellae in acute infections of the lower respiratory tract. Rev. Infect. Dis. **10:**1018–1028.
- 37. **Robinson, D., K. Shibuya, A. Mui, F. Zonin, E. Murphy, T. Sana, S. B. Hartley, S. Menon, R. Kastelein, F. Bazan, and A. O'Garra.** 1997. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity **7:**571–581.
- 38. **Salins, S., C. Newton, R. Widen, T. W. Klein, and H. Friedman.** 2001. Differential induction of gamma interferon in *Legionella pneumophila*-infected macrophages from BALB/c and A/J mice. Infect. Immun. **69:**3605– 3610.
- 39. **Sing, A., A. Roggenkamp, A. M. Geiger, and J. Heesemann.** 2002. *Yersinia enterocolitica* evasion of the host innate immune response by V antigeninduced IL-10 production of macrophages is abrogated in IL-10-deficient mice. J. Immunol. **168:**1315–1321.
- 40. **Sing, A., D. Rost, N. Tvardovskaia, A. Roggenkamp, A. Wiedemann, C. J. Kirschning, M. Aepfelbacher, and J. Heesemann.** 2002. *Yersinia* V-antigen exploits Toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J. Exp. Med. **196:**1017–1024.
- 41. **Skerrett, S. J., and T. R. Martin.** 1994. Intratracheal interferon-gamma augments pulmonary defenses in experimental legionellosis. Am. J. Respir. Crit. Care Med. **149:**50–58.
- 42. **Swanson, M. S., and B. K. Hammer.** 2000. *Legionella pneumophila* pathogenesis: a fateful journey from amoebae to macrophages. Annu. Rev. Microbiol. **54:**567–613.
- 43. **Swanson, M. S., and R. R. Isberg.** 1995. Association of *Legionella pneumophila* with the macrophage endoplasmic reticulum. Infect. Immun. **63:**3609– 3620.
- 44. **Tateda, K., J. C. Deng, T. A. Moore, M. W. Newstead, R. Paine III, N. Kobayashi, K. Yamaguchi, and T. J. Standiford.** 2003. Hyperoxia mediates acute lung injury and increased lethality in murine *Legionella* pneumonia: the role of apoptosis. J. Immunol. **170:**4209–4216.
- 45. **Tateda, K., T. Matsumoto, Y. Ishii, N. Furuya, A. Ohno, S. Miyazaki, and K. Yamaguchi.** 1998. Serum cytokines in patients with *Legionella* pneumonia: relative predominance of Th1-type cytokines. Clin. Diagn. Lab. Immunol. **5:**401–403.
- 46. **Tateda, K., T. A. Moore, J. C. Deng, M. W. Newstead, X. Zeng, A. Matsukawa, M. S. Swanson, K. Yamaguchi, and T. J. Standiford.** 2001. Early recruitment of neutrophils determines subsequent T1/T2 host responses in a murine model of *Legionella pneumophila* pneumonia. J. Immunol. **166:**3355– 3361.
- 47. **Tkatch, L. S., S. Kusne, W. D. Irish, S. Krystofiak, and E. Wing.** 1998. Epidemiology of *Legionella* pneumonia and factors associated with legionella-related mortality at a tertiary care center. Clin. Infect. Dis. **27:**1479– 1486.
- 48. **Ushio, S., M. Namba, T. Okura, K. Hattori, Y. Nukada, K. Akita, F. Tanabe, K. Konishi, M. Micallef, M. Fujii, K. Torigoe, T. Tanimoto, S. Fukuda, M. Ikeda, H. Okamura, and M. Kurimoto.** 1996. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in *Escherichia coli*, and studies on the biologic activities of the protein. J. Immunol. **156:**4274–4279.
- 49. **Wiese, A., M. Munstermann, T. Gutsmann, B. Lindner, K. Kawahara, U. Zahringer, and U. Seydel.** 1998. Molecular mechanisms of polymyxin Bmembrane interactions: direct correlation between surface charge density and self-promoted transport. J. Membr. Biol. **162:**127–138.
- 50. **Wilson, M., R. Seymour, and B. Henderson.** 1998. Bacterial perturbation of cytokine networks. Infect. Immun. **66:**2401–2409.
- 51. **Yamamoto, Y., T. W. Klein, C. A. Newton, R. Widen, and H. Friedman.** 1988. Growth of *Legionella pneumophila* in thioglycolate-elicited peritoneal macrophages from A/J mice. Infect. Immun. **56:**370–375.
- 52. **Yoshimoto, T., H. Okamura, Y. I. Tagawa, Y. Iwakura, and K. Nakanishi.** 1997. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. Proc. Natl. Acad. Sci. USA **94:**3948–3953.
- 53. **Zhang, T., K. Kawakami, M. H. Qureshi, H. Okamura, M. Kurimoto, and A. Saito.** 1997. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against *Cryptococcus neoformans* through production of gamma interferon by natural killer cells. Infect. Immun. **65:**3594–3599.
- 54. **Zink, S. D., L. Pedersen, N. P. Cianciotto, and Y. Abu-Kwaik.** 2002. The Dot/Icm type IV secretion system of *Legionella pneumophila* is essential for the induction of apoptosis in human macrophages. Infect. Immun. **70:**1657– 1663.